Influenza is now occurring in many areas of the country, and health care professionals are confronted with therapeutic decisions for large numbers of patients with flu-like symptoms. Among other factors, they may consider whether to use one of the four drugs currently approved for antiviral therapy in uncomplicated influenza. While health care professionals and consumers are becoming familiar with the treatment options, FDA's advisory provides several considerations for health care professionals treating flu patients.
Vaccination remains the primary method of preventing and controlling influenza.
This product may carry risk, in patients with severe or decompensated asthma or chronic obstructive pulmonary disease. Bronchospasm was documented in some patients with mild or moderate asthma following administration of zanamivir. Any patient who develops bronchospasm should stop the drug and call their health care provider. Patients with underlying respiratory disease should be instructed to have a fast-acting inhaled bronchodilator available when they are being treated with zanamivir. The Relenza package insert contains important precautionary information regarding risk of bronchospasm in patients with respiratory disease.